oc9b00956_si_001.pdf (2.82 MB)
Glycoengineering of Natural Killer Cells with CD22 Ligands for Enhanced Anticancer Immunotherapy
journal contribution
posted on 2020-03-05, 16:58 authored by Xianwu Wang, Shuyao Lang, Yunpeng Tian, Jianghong Zhang, Xu Yan, Zhihong Fang, Jian Weng, Na Lu, Xuanjun Wu, Tianlu Li, Hongzhi Cao, Zhu Li, Xuefei HuangAdoptive transfer
of immune cells is being actively pursued for
cancer treatment. Natural killer (NK) cells, a class of cytotoxic
immune cells, generally lack inherent selectivities toward cancer.
To bestow tumor-targeting abilities and enhance anticancer efficacy,
a new strategy is established to glycoengineer NK cells. Carbohydrate-based
ligands for CD22, a marker for B cell lymphoma, are introduced onto
NK cells through either metabolic engineering or glyco-polymer insertion.
Such NK cells exhibited greatly enhanced cytotoxicities toward CD22+ lymphoma cells in a CD22-dependent manner. Importantly, both
CD22+ lymphoma cell lines and primary lymphoma cells from
human cancer patients can be effectively killed by the engineered
NK cells. Furthermore, glycoengineered NK cells provided significant
protection to tumor-bearing mice. Thus, NK cell glycoengineering is
an exciting new approach for cancer treatment complementing the current
immune cell genetic engineering strategy.